David G. Coffey

2.4k total citations · 1 hit paper
57 papers, 1.4k citations indexed

About

David G. Coffey is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, David G. Coffey has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 28 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in David G. Coffey's work include Multiple Myeloma Research and Treatments (36 papers), CAR-T cell therapy research (14 papers) and Protein Degradation and Inhibitors (13 papers). David G. Coffey is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), CAR-T cell therapy research (14 papers) and Protein Degradation and Inhibitors (13 papers). David G. Coffey collaborates with scholars based in United States, South Africa and Australia. David G. Coffey's co-authors include Damian J. Green, Andrew J. Cowan, Edward N. Libby, Sherilyn A. Tuazon, Ajay K. Gopal, Leona Holmberg, Mary Kwok, Sarah Lee, Edus H. Warren and Steven E. Robinson and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

David G. Coffey

48 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and Management of Multiple Myeloma

2022 526 citations Andrew J. Cowan, Damian J. Green et al. profile →

Peers

David G. Coffey

ONCOL

HEMAT

IMMUN

Wencai Ma United States

Frédéric Barabé Canada

Masahito Kawazu Japan

Martín Pérez‐Andrés Spain

Baldev Vasir United States

Nikoletta Lendvai United States

Jeong Hee Cho‐Vega United States

Xianmin Song China

Donald G. Morris Canada

Wencai Ma United States

David G. Coffey

872 ×1.2

535 ×0.8

ONCOL

490 ×0.8

HEMAT

570 ×1.8

IMMUN

134 ×0.6

Citations per year, relative to David G. Coffey David G. Coffey (= 1×) peers Wencai Ma

Countries citing papers authored by David G. Coffey

Since Specialization

Citations

This map shows the geographic impact of David G. Coffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Coffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Coffey more than expected).

Fields of papers citing papers by David G. Coffey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Coffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Coffey. The network helps show where David G. Coffey may publish in the future.

Co-authorship network of co-authors of David G. Coffey

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Coffey. A scholar is included among the top collaborators of David G. Coffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Coffey. David G. Coffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peterson, Alexander C., Aaron Baraff, Jennifer L. Barton, et al.. (2025). Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis. BMC Rheumatology. 9(1). 7–7.

Coffey, David G., Keren Osman, Adolfo Aleman, et al.. (2024). Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. Journal for ImmunoTherapy of Cancer. 12(4). e008110–e008110. 5 indexed citations

Coffey, David G., Valentin Voillet, Ilan R. Kirsch, et al.. (2024). Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor–Adoptive T-cell Therapy. Blood Cancer Discovery. 5(4). 258–266. 2 indexed citations

Thoren, Katie, Dan Qu, James E. Hoffman, et al.. (2024). Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry. Blood. 144(Supplement 1). 6847–6847.

Kowalski, Andrew S., David G. Coffey, Benjamin Diamond, et al.. (2024). Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma. Blood. 144(Supplement 1). 2389–2389.

Coffey, David G., Pınar Ataca Atilla, Erden Atilla, et al.. (2024). Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy. Blood. 145(2). 220–233. 6 indexed citations

Qu, Dan, et al.. (2024). Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review. Annals of Hematology. 103(10). 4313–4317. 1 indexed citations

Maura, Francesco, David G. Coffey, Caleb K. Stein, et al.. (2024). The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans. Nature Communications. 15(1). 3844–3844. 4 indexed citations

Cowan, Andrew J., Margot J. Pont, Blythe Sather, et al.. (2023). γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. The Lancet Oncology. 24(7). 811–822. 52 indexed citations

10.

Libby, Edward N., Andrew J. Cowan, Mary Kwok, et al.. (2022). Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed. American Journal of Clinical Oncology. 45(11). 443–449. 1 indexed citations

11.

Towlerton, Andrea, et al.. (2022). Serial Analysis of the T-Cell Receptor β-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy. Frontiers in Immunology. 13. 879190–879190. 4 indexed citations

12.

Coffey, David G., Yuexin Xu, Andrea Towlerton, et al.. (2022). Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. Frontiers in Immunology. 13. 961105–961105.

13.

Cowan, Andrew J., Damian J. Green, Mehdi Karami, et al.. (2020). KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 20(9). 602–609. 5 indexed citations

14.

Cowan, Andrew J., Philip A. Stevenson, Edward N. Libby, et al.. (2018). Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. Biology of Blood and Marrow Transplantation. 24(7). 1386–1391. 19 indexed citations

15.

Coffey, David G., Christopher S. Carlson, Andrea Towlerton, et al.. (2017). High-throughput sequencing reveals novel features of immunoglobulin gene rearrangements in Burkitt lymphoma. Blood Advances. 1(16). 1261–1262. 1 indexed citations

16.

Coffey, David G., Christopher S. Carlson, Andrea Towlerton, et al.. (2017). High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis. Blood Advances. 1(9). 535–544. 17 indexed citations

17.

Kanakry, Christopher G., David G. Coffey, Andrea Towlerton, et al.. (2016). Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight. 1(5). 97 indexed citations

18.

Cowan, Andrew J., Zandra Klippel, Philip A. Stevenson, et al.. (2016). Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Amyloid. 23(4). 254–259. 5 indexed citations

19.

Zhou, Qing, David G. Coffey, Steven L. Highfill, et al.. (2014). Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis. PLoS ONE. 9(6). e100629–e100629. 10 indexed citations

20.

Jubala, Cristan M., Julie Lang, David G. Coffey, et al.. (2008). MHC-dependent desensitization of intrinsic anti-self reactivity. Cancer Immunology Immunotherapy. 58(2). 171–185. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact